Replies to post #6169 on Provectus Biopharmaceuticals Inc (PVCT)

[vorlon1966]

The articles I posted do not show up well on phones
I just checked
Review on your computer please

There is an established process where the data monitoring committee reviews the progress of the study
It is FDA standard procedure to not run a pIII to the end if the data shows real improvement over the comparator ... It is considered unethical in oncology cases

The only reasons to run it to the end is if the data is just so so and you need the numbers to see the significance

The links I provided explains in detail those rules

By my post I am assuming such significance will be shown

Again I apologize for the confusion

http://mobile.bloomberg.com/news/2014-03-31/novartis-says-final-phase-study-on-heart-drug-was-successful.html